ARGX
argenx SE · NASDAQ
- Market cap
- $58.81B
52-week range70% up the range
$662.47$1072.33
argenx SE (ARGX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for ARGX, including 4 SEC filings, 2 press releases and news items and 2 M&A updates. The most recent was published Nov 9, 2026.
ARGX rankings
Price$947.40-40.89 (-4.14%)
2026-08-172026-11-17
Financial highlights
Full financials- Revenue, FY2025
- $4.25B
- Revenue growth
- +88.6%
- Net income, FY2025
- $1.29B
- Net margin
- 30.4%
- Free cash flow, FY2025
- $679.03M
- Cash
- $3.49B
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks47-40%
2026-05-242026-11-15
Mix2390d
- SEC Filings8(35%)
- Other7(30%)
- M&A3(13%)
- Analyst2(9%)
- Earnings2(9%)
- Leadership1(4%)
Activity · 52 weeks8448 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Our reporting on ARGX
Latest news
25 items- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology CapabilitiesPairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biologyExtends argenx’s immunology innovation to more patients, with the potential for oral and long-acting medicines Builds on more than two years of collaboration and investment; UNP to continue operating from Santa Cruz, California with its current team, preserving the science-first culture behind its success Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its
- PRUnnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation MedicinesArgenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion Acquisition builds on the two-year multi-target research collaboration UNP’s team and macrocycle platform to continue as argenx’s dedicated macrocyclic peptide discovery hub in Santa Cruz SANTA CRUZ, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced that it has entered into a definitive agreement to be acquired by argenx ((Euronext &, NASDAQ:ARGX), a global immuno
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by argenx SESCHEDULE 13G/A - ARGENX SE (0001697862) (Subject)
- PRargenx to Present at Upcoming Investor ConferencesNovember 3, 2026 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m. ET in Boston, MA.Jefferies London Global Healthcare Conference. Fireside chat on Tuesday, November 17 at 8:30 a.m. GMT in London, UK. A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days follo
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Reports Third Quarter 2026 Financial Results and Provides Business UpdateContinued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing additional registrational study in DM Phase 3 MMN data for empasiprubart expected in December 2026 FB102 advancing to Phase 3 in celiac disease as potential new growth pillar in argenx’s next wave of immunology innovation Management to host conference call today at 2:30 PM CET (8:30 AM ET) October 22, 2026 7:00 AM CET Amsterdam, the Netherlands - argenx SE ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced its third qu
- PRargenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET October 19, 2026, 8:00 AM ET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced that new data from the Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis, focused on immune-mediated necrotizin
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026October 15, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Count
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseOctober 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded that the UNITY study is unable to meet its primary endpoint. Safety was consistent with efgartigimod's established profile and no new safety signals were identified. "We are disappointed b
- PRargenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseStudy met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following argenx’s acquisition of Forte Biosciences in August 2026. Patients treated wi
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular PipelineNew data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data reinforce VYVGART’s consistent safety and efficacy profile in CIDP, and Phase 4 switch data support the feasibility of a direct, one-week transition from IVIg Empasiprubart Phase 2 study results in MMN support its potential as a pathway-selective complement therapy September 29, 2026, 8:00 AM EST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation c
- PRargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsSeptember 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors. "We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as ever before, on our scientific innovation mission, delivering value for shareholders, and always deepening the impact we make for patients and their communities. As we look ahead to Vision 2030 and
- PRargenx to Present at Upcoming Investor ConferencesSeptember 1, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY. A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approx
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by argenx SESC TO-T/A - ARGENX SE (0001697862) (Filed by)
- PRargenx Completes Acquisition of Forte Biosciences, Inc.Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. ("Forte") (NASDAQ:FBRX). The acquisition expands argenx’s portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. The acquisition reflects argenx’s disciplined approach to identifying and advancing breakthrough science fo
- ANALYSTargenx upgraded by UBS with a new price targetUBS upgraded argenx from Neutral to Buy and set a new price target of $1,400.00
- ANALYSTargenx downgraded by Deutsche BankDeutsche Bank downgraded argenx from Buy to Hold
- SECAmendment: SEC Form SC TO-T/A filed by argenx SESC TO-T/A - ARGENX SE (0001697862) (Filed by)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
ARGX FAQ
11 questionsWhat does argenx SE do?
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with...What is the latest news on ARGX?
In the last 30 days Quantisnow tracked 10 wire items for ARGX: 4 SEC filings, 2 press releases and news items, 2 M&A updates and 1 earnings update. The most recent was published on November 9, 2026.What is ARGX revenue?
argenx SE (ARGX) reported $4.25B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 88.6% from the year before.Is ARGX profitable?
Yes. argenx SE earned $1.29B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 30.4%.How much cash and debt does ARGX have?
argenx SE reported $3.49B in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ARGX stock trade?
argenx SE (ARGX) is listed on NASDAQ.What sector and industry is ARGX in?
argenx SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did argenx SE go public?
argenx SE (ARGX) completed its IPO in 2017.What are analysts saying about ARGX?
Across the last 8 analyst actions on argenx SE, there were 2 upgrades and 4 downgrades. The most recent action was from UBS: Buy with a $1400.00 price target on 2026-08-26. Recent price targets range from $858.00 to $1400.00.What companies are similar to ARGX?
Notable peers in the same industry include SNY (Sanofi), AMGN (Amgen Inc.), ALNY (Alnylam Pharmaceuticals Inc.), IMVT (Immunovant Inc.), HRMY (Harmony Biosciences Holdings Inc.). Compare ARGX side-by-side with any of them on Quantisnow.How can I track ARGX on Quantisnow?
Quantisnow aggregates argenx SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARGX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change
